After roping in $175M+ at the beginning of the year, Metagenomi opens the doors to a new manufacturing site
The gene editing biotech Metagenomi has been on a roll for the past few years. Coming out of the gate in 2020, it had $65 million in cash from Bayer’s investment arm, and just this year it brought in a $175 million Series B. Now it has taken the next step and opened a GMP manufacturing facility on its 50,000 square-foot campus in Emeryville, CA.
The facility, which will have two clean rooms and a modular design, will aim to produce the biotech’s gene editing tools as well as scale up the production of nucleases for either partnered or in-house therapeutic programs.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
